April 8, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

High-dose Stereotactic Body Radiotherapy Well-tolerated by Patients with Centrally-located Lung Tumors  Read more


Andrea Bezjak, MD

ACTIVATIONS

GYNECOLOGIC

NRG-GY014: Activation Date: March 29, 2019 (posted on CTSU)

 

LUNG

NRG-LU003: Activation Date: April 1, 2019 (posted on CTSU)

 

Cancer Care Delivery Research

NRG-CC007CD: Activation Date: March 27, 2019. This trial is open to NCORP sites only. See the study memo on study-specific page on CTSU (posted under Supplemental documents).


TERMINATIONS
GYNECOLOGIC

NRG-GY001: Termination effective February 9, 2019; version date: February 17, 2017 (posted on CTSU)

 

GOG-9926: Termination and Amendment 6 effective February 9, 2019; version date: December 22, 2014 (posted on NRG Oncology)


OTHER PROTOCOL NOTICES

1. COLORECTAL

NRG-GI002: IMPORTANT NOTICE! NRG Oncology is closely monitoring accrual to this rapidly enrolling trial. (Information posted on  CTSU)

 

2. GYNECOLOGIC

NRG-GY007: Currently accruing to the Phase II portion Read more

 

NRG-GY009: Block Submission Reminder memo (posted on  CTSU)

 

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more

 

Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more

 

3. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, April 10, 2019.

DRUG SAFETY UPDATES AND INVESTIGATOR'S BROCHURE NOTICES 

Safety updates and Investigator’s Brochure notices have been issued for the following studies:

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

INVESTIGATOR'S BROCHURE (IB)*

AMG 232

NRG-DT001

 

X

Durvalumab

 

NRG-HN004

NRG-LU004

CTSU

NRG

 

Nivolumab

NRG-BN002

NRG-GY003

NRG

NRG

 

Olaparib

NSABP B-55

CTSU

 

Pembrolizumab

NRG-GI002

NRG-GY016

NRG-HN003

CTSU

CTSU

NRG

 

Triapine

NRG-GY006

CTSU

 


*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website ( https://ctepcore.nci.nih.gov/OAOP/.  Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

 

 

Updated NCI Investigational Agent Accountability Record Form

The NCI Investigational Agent Accountability Record Forms have been updated. Please use the current versions located on the CTEP website.

 

NRG Oncology Semiannual Meeting

SAVE-THE-DATE: Patient Reported Outcomes: Upping the game for PRO methods and design in clinical trials

NRG Oncology will be holding a workshop at the NRG Semiannual Meeting related to improving statistical methods to meet study goals, analyzing longitudinal PRO data as well as a panel discussion with NCORP PIs. This session will be held on Thursday, July 18, 2019 from 1-5 pm ET and will be open to all attendees. More information on the session, agenda and location will be released soon.

 

High-dose Stereotactic Body Radiotherapy Well-tolerated by Patients with Centrally-located Lung Tumors

Stereotactic Body Radiotherapy (SBRT), a high-dose, precisely delivered radiotherapy, is considered the standard treatment for patients with medically inoperable, node-negative, non-small cell lung cancer (NSCLC). However, this well-tolerated radiation treatment was not previously tested in centrally-located NSCLC due to the fact that patients with centrally located lung tumors demonstrate a higher risk for toxicity if treated with high SBRT doses. Read more

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.


JOURNAL ARTICLES

 Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, Garces YI, Pu AT, Singh AK, Videtic GM, McGarry RC, Iyengar P, Pantarotto JR, Urbanic JJ, Sun AY, Daly ME, Grills IS, Sperduto P, Normolle DP, Bradley JD, Choy H. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019 Apr 3:JCO1800622. doi: 10.1200/JCO.18.00622. [Epub ahead of print] PubMed PMID: 30943123.   Read more

 

Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019 Apr 1; 103(5):1077-1084. doi: 10.1016/j.ijrobp.2018.11.051. Epub 2018 Dec 1. PubMed PMID: 30513377.   Read more


PUBLICATIONS REMINDERS

Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings

American Association for Thoracic Surgery (AATS); May 4-7, 2019; Toronto, ON

American College of Radiology (ACR); May 18-22, 2019 ; Washington DC

ESMO Breast Cancer Annual Congress; May 2-4, 2019; Berlin, Germany

European Society for Radiotherapy and Oncology (ESTRO); Apr 26-30, 2019; Milan, Italy

Society for Clinical Trials (SCT); May 19-22, 2019; New Orleans, LA


Upcoming Abstract Submission Deadlines

European Society of Gynaecolocial Oncology (ESGO) Biennial; Nov 2-5, 2019; Athens, Greece; due to publications committee Apr 19, 2019; meeting submission deadline May 3, 2019

European Society for Medical Oncology (ESMO); Sep 27-Oct 1, 2019; Barcelona, Spain; due to publications committee Apr 30, 2019; meeting submission deadline May 8, 2019 9 pm CEST (Central European Summer Time); LBA Aug 21, 2019 9:00 pm CEST

International Gynecologic Cancer Society (IGCS); Sep 19-20, 2019; Rio de Janeiro, Brazil; due to publications committee Apr 8, 2019; meeting submission deadline Apr18, 2019

International Society for Quality of Life Research (ISOQOL); Oct 20-23, 2019; San Diego, CA; meeting submission deadline Apr 8, 2019

Radiological Society of North America (RSNA); Dec 1-6, 2019; Chicago, IL; meeting submission deadline Apr 10, 2019

Radiological Society of North America (RSNA); Dec 1-6, 2019; Chicago, IL; meeting submission deadline Apr 10, 2019

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse